Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its first quarter 2016 financial and operating results on Wednesday, May 4, 2016 before the market opens. The company will host a conference call to discuss these results on Wednesday, May 4, 2016 at 8:30 a.m. Eastern Time.

To access the call live, please dial 416-340-2216 or 1-866-225-2055. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 11:59 p.m. Eastern Time on Wednesday, May 11, 2016 by dialing 905-694-9451 or 1-800-408-3053, using access code: 8416341#.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. GYNOFLOR™, a product licensed to Acerus in Canada by Medinova AG and approved in 39 countries worldwide, is an ultra-low dose vaginal estrogen therapy with the addition of lactobacillus, for the treatment of atrophic vaginitis, certain vaginal infections and/or to restore a healthy vaginal environment. TEFINA™, a ‘use as required’ nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female sexual dysfunction.

For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Acerus Pharmaceuticals CorporationTiana DiMichele, 416-679-0822Director, Marketing & Communicationstdimichele@aceruspharma.com

Acerus Pharmaceuticals (TSX:ASP)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Acerus Pharmaceuticals.
Acerus Pharmaceuticals (TSX:ASP)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Acerus Pharmaceuticals.